Tryp Therapeutics Inc (TRYPF) Corporate Presentation

Corporate Presentation Fall 2021 LEADING THE NEXT WAVE OF PSYCHEDELIC DRUG DEVELOPMENT Tryp’s differentiated approach to psychedelic drug development has the potential to deliver urgently needed treatments to millions of patients suffering from chronic pain and other diseases while creating significant opportunity for investors. 38 1. Unique, highly valuable indications Our imminent Phase 2a clinical trials represent the first time that any type of psychedelic has been evaluated for the respective indications in a Phase 2 study. Fibromyalgia, phantom limb pain, CRPS, binge eating disorder, and hypothalamic obesity represent more than $12 billion of potential peak annual sales upon successful commercialization. 2. A proprietary formulation and delivery method TRPՓ8803, our novel formulation, is poised to disrupt the dosing and administration of psilocybin-based drug products, with the aim of creating a better patient experience. 3. Exclusive manufacturing Our exclusive supply of synthetic psilocybin provides a rare capability among psychedelic drug development companies with ample material to meet all of our clinical trial and commercialization needs. 4. The right people at the right time We are constantly expanding our roster of both internal and collaborative experts to drive world-class outcomes. We are well positioned for success: